Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab β + PRaG Regimen in EGFR-positive Advanced Refractory Solid Tumors
NCT07327411Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in solid tumor (advanced stage), sponsored by The Second Affiliated Hospital of Soochow University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07327411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327411.